| abstract |
An inhibitor of a receptor tyrosine kinase, in particular selected from a compound of formula (I), (II) or (III) as defined in the specification for use in the treatment of fascioscapulohumeral dystrophy (FSHD)wherein formula (I) is exemplified by (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl- H-pyrrole-3-carboxamide(sunitinib),formula (II) is exemplified by (N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4- pyrimidinyl]amino]-benzenesulfonamide (TG101209) and formula (III) is exemplified 10 by N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine)(Vandetanib). |